Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2006 1
2007 1
2008 1
2012 1
2013 3
2014 2
2015 3
2016 2
2017 1
2018 1
2019 3
2020 1
2021 5
2022 4
2023 2
2024 2
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C; French Cystic Fibrosis Reference Network study group. Burgel PR, et al. Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13. Lancet Respir Med. 2024. PMID: 39151434
Prevention of osteoporosis in cystic fibrosis.
Chedevergne F, Sermet-Gaudelus I. Chedevergne F, et al. Curr Opin Pulm Med. 2019 Nov;25(6):660-665. doi: 10.1097/MCP.0000000000000624. Curr Opin Pulm Med. 2019. PMID: 31567515 Review.
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I; French CF Reference Network study group. Dreano E, et al. Eur Respir J. 2023 Oct 19;62(4):2300110. doi: 10.1183/13993003.00110-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37696564 Free article.
Predictive factors for lumacaftor/ivacaftor clinical response.
Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, Flament T, Le Bourgeois M, Chedevergne F, Bailly C, Kyrilli S, Achimastos D, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Masson A, et al. J Cyst Fibros. 2019 May;18(3):368-374. doi: 10.1016/j.jcf.2018.12.011. Epub 2018 Dec 28. J Cyst Fibros. 2019. PMID: 30595473 Free article.
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis.
Truong NH, Benaboud S, Bouazza N, Barboura M, Bardin E, Miralles M, Lui G, Froelicher-Bournaud L, Rouillon S, Bihouee T, Bui S, Reix P, Dalphin ML, Laurans M, Languepin J, Corvol H, Troussier F, Weiss L, Cinthia R, Tatopoulos A, Deneuville E, Chiron R, Stremler N, Llerena C, Ramel S, Perisson C, Houdoin V, Mittaine M, Treluyer JM, Sermet-Gaudelus I, Foissac F; MODUL‐CF study group. Truong NH, et al. Clin Transl Sci. 2025 May;18(5):e70245. doi: 10.1111/cts.70245. Clin Transl Sci. 2025. PMID: 40347054 Free PMC article.
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study.
Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, Foissac F, Truong NH, Benhamida M, Arnouat B, Borghese R, Chedevergne F, Couderc-Kohen L, da Silva J, Grenet D, Houdouin V, Le A, Marchal S, Deneuville E, Pouradier D, Rousseau V, Treluyer JM, Francart A, Steffann J, Reix P, Benaboud S, Mamzer MF, Ville Y, Martin C, Burgel PR, Sermet-Gaudelus I; MODUL-CF study group. Bonnel AS, et al. J Cyst Fibros. 2025 May;24(3):457-465. doi: 10.1016/j.jcf.2025.03.009. Epub 2025 Mar 24. J Cyst Fibros. 2025. PMID: 40133101
The role of inflammation in childhood asthma.
Chedevergne F, Le Bourgeois M, de Blic J, Scheinmann P. Chedevergne F, et al. Arch Dis Child. 2000 Jun;82 Suppl 2(Suppl 2):II6-9. doi: 10.1136/adc.82.suppl_2.ii6. Arch Dis Child. 2000. PMID: 10833470 Free PMC article. Review.
Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis.
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin ML, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud MC, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel AS, Sermet-Gaudelus I; MODUL CF group. Galderisi A, et al. J Clin Endocrinol Metab. 2025 Feb 20:dgaf099. doi: 10.1210/clinem/dgaf099. Online ahead of print. J Clin Endocrinol Metab. 2025. PMID: 39977216
[Inhaled treatments in cystic fibrosis: what's new in 2013?].
Dubus JC, Bassinet L, Chedevergne F, Delaisi B, Desmazes-Dufeu N, Reychler G, Vecellio L; GRAM (Groupe aérosols et mucoviscidose de la Société française de mucoviscidose). Dubus JC, et al. Rev Mal Respir. 2014 Apr;31(4):336-46. doi: 10.1016/j.rmr.2013.12.001. Epub 2014 Jan 4. Rev Mal Respir. 2014. PMID: 24750953 Review. French.
37 results